Intensity Therapeutics, Inc.
Monday, February 26, 2024
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers.
CEO/Top Company Official
Lead Product in Development
Phase 3 for a superiority trial of the Company's lead product INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes.
Development Phase of Primary Product
Number Of Unlicensed Products